Rominger K L, Schäfer E, Vrecko H G, Palme M
Boehringer Ingelheim KG, Abteilung Biochemie und Medizin, Ingelheim/Rhein.
Arzneimittelforschung. 1991 Apr;41(4):399-401.
Concentrations of clonidine (CAS 4205-09-7. Catapresan) were measured in the plasma and the urine of 6 patients with delirium tremens who received 1.8-13.8 mg clonidine on the third treatment day. There was a linear correlation between the daily dose of clonidine and the steady state concentration of clonidine in the plasma, even with the high doses of clonidine used in this study. The total clonidine clearance was 29-62% lower than in normal volunteers. The renal clearance were 49-75% lower than normal. The renal excretion of the non-metabolized clonidine was significantly lower than the normal range. The creatinine clearance on the other hand was only slightly reduced. The present study gives first hints that the metabolic clearance of clonidine in patients with delirium tremens is not decreased remarkably.
在6例震颤谵妄患者的血浆和尿液中测定了可乐定(CAS 4205-09-7, Catapresan)的浓度,这些患者在治疗的第三天接受了1.8 - 13.8毫克可乐定。即使在本研究中使用了高剂量的可乐定,可乐定的日剂量与血浆中可乐定的稳态浓度之间仍存在线性相关性。可乐定的总清除率比正常志愿者低29% - 62%。肾脏清除率比正常低49% - 75%。未代谢可乐定的肾脏排泄显著低于正常范围。另一方面,肌酐清除率仅略有降低。本研究首次表明,震颤谵妄患者中可乐定的代谢清除率没有显著降低。